Silenor doxepin regulatory update

Somaxon said Health Canada accepted for review an NDS for Silenor doxepin to treat insomnia. Last year, Somaxon granted Paladin Labs Inc. (TSX:PLB, Montreal, Quebec) exclusive rights to commercialize...